IV Diltiazem Conversion and Administration

Introduction to IV Diltiazem Administration

The American College of Cardiology recommends an initial bolus of 0.25 mg/kg (approximately 15-20 mg for average adult) IV over 2 minutes for acute rate control, with a possible second bolus of 0.35 mg/kg if inadequate response after 15 minutes 1
The American College of Cardiology suggests that after bolus dosing, continuous infusion at 5-15 mg/hour is the standard approach for ongoing rate control, with infusion rates of 3, 5, 7, and 11 mg/hour producing steady-state concentrations equivalent to oral doses of 120, 180, 240, and 360 mg daily respectively 1

The American College of Cardiology states that no guideline or FDA labeling supports scheduled intermittent IV bolus dosing of diltiazem, and the drug is designed for either acute conversion (single or double bolus) or continuous infusion for sustained effect 1

For sustained rate control, the American College of Cardiology recommends using continuous IV infusion at approximately 5 mg/hour (equivalent to 180 mg oral daily), with titration of infusion rate based on heart rate and blood pressure response 1

The American College of Cardiology lists absolute contraindications before any IV diltiazem administration, including second or third-degree AV block without pacemaker, decompensated systolic heart failure or severe LV dysfunction, cardiogenic shock, and WPW syndrome with atrial fibrillation/flutter 1
The American College of Cardiology recommends essential monitoring, including continuous cardiac monitoring during and after administration, blood pressure monitoring every 5-15 minutes initially, and resuscitation equipment immediately available, as well as atropine and temporary pacing capability for severe bradycardia 1

The American College of Cardiology and American Heart Association recommend administering an initial dose of 0.25 mg/kg (approximately 20 mg for average adult) IV over 2 minutes, with assessment of response at 15 minutes after the first dose 2, 3, 4

The American College of Cardiology and American Heart Association recommend avoiding diltiazem administration in patients with AV block greater than first degree without pacemaker, decompensated systolic heart failure or LV dysfunction, hypotension, pre-excited atrial fibrillation/flutter (WPW syndrome), and cardiogenic shock 2, 3, 4
Resuscitation equipment should be available during administration, with atropine or temporary pacing capability for severe bradycardia 5, 6

The American College of Cardiology recommends an initial IV bolus of 0.25 mg/kg (≈15–20 mg for a typical adult) administered over 2 minutes for rapid rate control in acute atrial fibrillation before starting a maintenance infusion. 7
After the bolus, the American College of Cardiology advises initiating a continuous IV infusion of 5–15 mg/hour, titrating the rate according to the patient’s heart‑rate and blood‑pressure response. 7

The American College of Cardiology states that IV diltiazem must not be given to patients with second‑ or third‑degree atrioventricular block without a functioning pacemaker, decompensated systolic heart failure or severe left‑ventricular dysfunction, cardiogenic shock, or Wolff‑Parkinson‑White syndrome presenting with atrial fibrillation/flutter. 7

To mitigate the risk of hypotension, the American College of Cardiology recommends delivering the infusion slowly at 2.5 mg/min for up to 20 minutes when hypotension is a concern. 7

According to the American College of Cardiology, because diltiazem is both a CYP3A4 substrate and a moderate CYP3A4 inhibitor, clinicians should reduce the warfarin dose by roughly 50 % and decrease the digoxin dose by 30–50 % when initiating diltiazem therapy. 7